Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft tissue sarcoma patients

O. Mir; S. Watson; C. Massard; A. Le Cesne; K. A. Benhadji; J. C. Soria

doi:10.1016/j.annonc.2020.09.003

Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft tissue sarcoma patients

O. Mir, S. Watson, C. Massard, A. Le Cesne, K. A. Benhadji, J. C. Soria

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

2 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	1782-1784
Nombre de pages	3
journal	Annals of Oncology
Volume	31
Numéro de publication	12
Les DOIs	https://doi.org/10.1016/j.annonc.2020.09.003
état	Publié - 1 déc. 2020

Accès au document

10.1016/j.annonc.2020.09.003

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{a45d636787884c6ba1b4767215869527,

title = "Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft tissue sarcoma patients",

author = "O. Mir and S. Watson and C. Massard and {Le Cesne}, A. and Benhadji, {K. A.} and Soria, {J. C.}",

note = "Funding Information: None declared. OM has received consultancy fees from Bayer, Blueprint Medicines, Bristol-Myers Squibb, Eli Lilly, Ipsen, Janssen, Lundbeck, Merck Sharpe & Dohme, Pfizer, Roche, Servier, and Vifor Pharma. He is a shareholder of Amplitude Surgical, Ipsen, and Transgene. SW has declared no conflicts of interest. CM has received consultancy fees from Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, Bristol-Myers Squibb, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, Merck Sharpe & Dohme, Novartis, Orion, Pfizer, Roche, and Sanofi. ALC has received consultancy fees from Amgen, Bayer, Eli-Lilly, Novartis, PharmaMar, and Pfizer. KAB reports employment by Eli Lilly and stock holding of Eli Lilly; KAB has been a full-time employee of Taiho Oncology since January 2019. JCS has received consultancy fees from AstraZeneca, Astex, Clovis, GlaxoSmithKline, GamaMabs, Lilly, Merck Sharpe & Dohme, Mission Therapeutics, Merus, Pfizer, PharmaMar, Pierre Fabre, Roche/Genentech, Sanofi, Servier, Symphogen, and Takeda and has been a full-time employee of MedImmune from September 2017 to December 2019. He is a shareholder of AstraZeneca and Gritstone.",

year = "2020",

month = dec,

day = "1",

doi = "10.1016/j.annonc.2020.09.003",

language = "English",

volume = "31",

pages = "1782--1784",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "12",

}

TY - JOUR

T1 - Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft tissue sarcoma patients

AU - Mir, O.

AU - Watson, S.

AU - Massard, C.

AU - Le Cesne, A.

AU - Benhadji, K. A.

AU - Soria, J. C.

N1 - Funding Information: None declared. OM has received consultancy fees from Bayer, Blueprint Medicines, Bristol-Myers Squibb, Eli Lilly, Ipsen, Janssen, Lundbeck, Merck Sharpe & Dohme, Pfizer, Roche, Servier, and Vifor Pharma. He is a shareholder of Amplitude Surgical, Ipsen, and Transgene. SW has declared no conflicts of interest. CM has received consultancy fees from Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, Bristol-Myers Squibb, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, Merck Sharpe & Dohme, Novartis, Orion, Pfizer, Roche, and Sanofi. ALC has received consultancy fees from Amgen, Bayer, Eli-Lilly, Novartis, PharmaMar, and Pfizer. KAB reports employment by Eli Lilly and stock holding of Eli Lilly; KAB has been a full-time employee of Taiho Oncology since January 2019. JCS has received consultancy fees from AstraZeneca, Astex, Clovis, GlaxoSmithKline, GamaMabs, Lilly, Merck Sharpe & Dohme, Mission Therapeutics, Merus, Pfizer, PharmaMar, Pierre Fabre, Roche/Genentech, Sanofi, Servier, Symphogen, and Takeda and has been a full-time employee of MedImmune from September 2017 to December 2019. He is a shareholder of AstraZeneca and Gritstone.

PY - 2020/12/1

Y1 - 2020/12/1

UR - http://www.scopus.com/inward/record.url?scp=85092618578&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2020.09.003

DO - 10.1016/j.annonc.2020.09.003

M3 - Letter

C2 - 32941988

AN - SCOPUS:85092618578

SN - 0923-7534

VL - 31

SP - 1782

EP - 1784

JO - Annals of Oncology

JF - Annals of Oncology

IS - 12

ER -